Table VII.
Co-expression of survivin and p53 in endometrial carcinoma according to scores of immunopositive cells in relation to clinicopathological parameters.
| Characteristics | Patients with survivin and p53 low scores positive expression, n (%) | Patients with either survivin or p53 moderate scores positive expression, n (%) | P-value |
|---|---|---|---|
| Age, years | |||
| <60 | 5 (71.4) | 18 (23.7) | 0.001 |
| ≥60 | 2 (28.6) | 58 (76.3) | |
| Histological type | |||
| Endometrioid | 7 (100.0) | 65 (85.5) | 0.676 |
| Clear cell and papillary serous | 0 (0.0) | 11 (14.5) | |
| Clinical stage | |||
| I | 6 (100.0) | 52 (78.8) | 0.320 |
| II | 0 (0.0) | 10 (15.2) | |
| III | 0 (0.0) | 4 (6.1) | |
| Histological differentiation | |||
| G1 | 3 (42.9) | 13 (17.1) | 0.315 |
| G2 | 4 (57.1) | 38 (50.0) | |
| G3 | 0 (0.0) | 25 (32.9) | |
| Myometrial invasion | |||
| <1/2 | 2 (28.6) | 27 (35.5) | 0.933 |
| ≥1/2 | 5 (71.4) | 49 (64.5) | |
| Lymph-vascular space invasion | |||
| Yes | 0 (0.0) | 11 (22.0) | 0.667 |
| No | 4 (100.0) | 39 (51.3) | |
| Fallopian tube and/or ovarian invasion | |||
| Yes | 0 (0.0) | 14 (37.8) | 0.027 |
| No | 3 (100.0) | 23 (62.2) | |
| Tumoral necrosis | |||
| Yes | 0 (0.0) | 5 (11.1) | 0.618 |
| No | 4 (100.0) | 40 (88.9) |
P<0.05, statistically significant results; 0.05<P<0.10, suggestive results.